FDA Approves Jazz Pharma’s Rylaze for Treating Common Leukemia in Children
Jazz Pharmaceuticals is flying high after hitting two back-to-back regulatory milestones late last month. The first was obtaining a seven-year Orphan Drug Exclusivity for Xywav, the latest contender from its …
Read More